Edgestream Partners L.P. bought a new stake in The Chemours Company (NYSE:CC - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 256,716 shares of the specialty chemicals company's stock, valued at approximately $3,473,000. Edgestream Partners L.P. owned approximately 0.17% of Chemours as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. FNY Investment Advisers LLC acquired a new stake in Chemours in the 1st quarter valued at about $27,000. UMB Bank n.a. lifted its position in shares of Chemours by 73.9% in the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 948 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Chemours by 170.7% in the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 1,444 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of Chemours by 100.4% in the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after purchasing an additional 1,119 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new position in Chemours in the fourth quarter worth approximately $48,000. Institutional investors own 76.26% of the company's stock.
Insiders Place Their Bets
In other news, insider Damian Gumpel bought 13,400 shares of the company's stock in a transaction on Monday, June 2nd. The stock was purchased at an average cost of $9.22 per share, for a total transaction of $123,548.00. Following the completion of the transaction, the insider owned 123,879 shares of the company's stock, valued at $1,142,164.38. This trade represents a 12.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Shane Hostetter acquired 4,450 shares of the stock in a transaction dated Monday, May 19th. The shares were bought at an average price of $11.28 per share, with a total value of $50,196.00. Following the completion of the transaction, the chief financial officer directly owned 59,694 shares of the company's stock, valued at $673,348.32. The trade was a 8.06% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 25,672 shares of company stock worth $251,573. Insiders own 0.47% of the company's stock.
Chemours Trading Down 0.7%
NYSE:CC traded down $0.10 on Friday, hitting $13.57. 2,983,453 shares of the stock were exchanged, compared to its average volume of 2,568,987. The stock has a market capitalization of $2.03 billion, a price-to-earnings ratio of 67.85 and a beta of 1.65. The Chemours Company has a 52 week low of $9.13 and a 52 week high of $24.64. The company has a debt-to-equity ratio of 7.01, a quick ratio of 0.83 and a current ratio of 1.75. The company's 50-day moving average price is $11.53 and its 200 day moving average price is $13.86.
Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.06). The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.36 billion. Chemours had a net margin of 0.54% and a return on equity of 23.82%. Chemours's revenue for the quarter was up .4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.32 earnings per share. On average, equities research analysts forecast that The Chemours Company will post 2.03 earnings per share for the current year.
Chemours Announces Dividend
The firm also recently declared a dividend, which was paid on Monday, June 16th. Investors of record on Monday, May 19th were paid a $0.0875 dividend. This represents a yield of 3.17%. The ex-dividend date of this dividend was Friday, May 16th. Chemours's dividend payout ratio (DPR) is presently 175.00%.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on CC shares. Truist Financial dropped their price objective on Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Morgan Stanley lowered their price objective on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Royal Bank Of Canada raised their target price on Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a research report on Thursday, July 3rd. Barclays reduced their target price on Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 28th. Finally, The Goldman Sachs Group cut their price objective on Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Chemours has an average rating of "Hold" and a consensus price target of $17.44.
Read Our Latest Report on Chemours
Chemours Company Profile
(
Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
See Also

Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report